The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, comments on the Phase I study of gilteritinib in combination with induction and consolidation therapy in subjects with newly diagnosed acute myeloid leukemia (AML)
Tags: ASH Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Published: 10 December 2018
Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the ...
Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and ...
Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her impression of the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her ...
Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ...
Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how ...
Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the purpose of targeting peripheral t-cell lymphoma (PTCL)
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...
Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us about the outcomes of the CARTITUDE-1 investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us ...
Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...
Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the ...
Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...
Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, shares the design of the TOURMALINE-AL1 study presented at ASH 2019
Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, elaborates on how the treatment of myelodysplastic syndromes is changing as a result of clinical data presented at ASH 2019
Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, tells us about Veneto-STOP study presented at ASH 2019
Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the the primary and secondary endpoints of the ECHELON-2 study
Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers whether off-the-shelf CAR-T cell therapies are becoming a reality
Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, elaborates on the outcomes from the TOURMALINE-AL1 study
Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some of the novel agents, targeted therapies, and emerging strategies in the management of acute myelogenous leukemia (AML)
Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us about the outcomes of the CARTITUDE-1 investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma
Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, tells us about the design and outcomes of the Phase 3 ELEVATE TN study, investigating acalabrutinib combined with obinutuzumab versus acalabrutinib alone versus obinutuzumab plus chlorambucil in patients with treatment-naive chronic lymphocytic leukemia (CLL)
Angela Dispenzieri, MD, speculates on the the clinical impact of the TOURMALINE-AL1 study
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, speculates on the the clinical impact of the TOURMALINE-AL1 study
Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the purpose of targeting peripheral t-cell lymphoma (PTCL)
Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinib
Dr. Tam, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, regarding the ideal patient profile in relapsed or refractory mantle cell lymphoma (MCL) for treatment with zanubrutinib
Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic factors in acute myeloid leukemia (AML) patients
Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL)
Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how JNJ-4528 differs from other CAR-T products
Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients
Dr. Park, Associate, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, shares clinical outcomes from the investigation of the vemurafenib combined with obinutuzumab in patients with hairy cell leukemia
Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, shares updates from the CLL14 study presented at ASH 2019 and elaborates on the role of debulking plays in the management of chronic lymphocytic leukemia (CLL)
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.